{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:51:26Z","timestamp":1777294286626,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["PHRC 2010"],"award-info":[{"award-number":["PHRC 2010"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["0906-EPPA153667-G"],"award-info":[{"award-number":["0906-EPPA153667-G"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4828-1","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T20:58:25Z","timestamp":1539205105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Lo\u00efc","family":"Lebellec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Bertucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Tresch-Bruneel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Bompas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ryckewaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Toiron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Camoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5243-1548","authenticated-orcid":false,"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-C\u00e9cile","family":"Le Deley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"4828_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.critrevonc.2010.10.007","volume":"80","author":"N Penel","year":"2011","unstructured":"Penel N, Marreaud S, Robin YM, Hohenberger P. Angiosarcoma: state of the art and perspectives. Crit Rev Oncol Hematol. 2011;80:257\u201363.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4828_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/annonc\/mdr138","volume":"23","author":"N Penel","year":"2012","unstructured":"Penel N, Italiano A, Ray-Coquard I, Chaigneau L, Delcambre C, Robin YM, et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012;23:517\u201323.","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"4828_CR3","doi-asserted-by":"publisher","first-page":"iii102","DOI":"10.1093\/annonc\/mdu254","volume":"25","author":"The ESMO\/European Sarcoma Network Working Group","year":"2014","unstructured":"The ESMO\/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii102\u201312.","journal-title":"Ann Oncol"},{"key":"4828_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.humpath.2009.08.021","volume":"41","author":"W Tokuyama","year":"2010","unstructured":"Tokuyama W, Mikami T, Masuzawa M, Okayasu I. Autocrine and paracrine roles of VEGF\/VEGFR-2 and VEGF-C\/VEGFR-3 signaling in angiosarcomas of the scalp and face. Hum Pathol. 2010;41:407\u201314.","journal-title":"Hum Pathol"},{"key":"4828_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1593\/neo.111770","volume":"14","author":"JR Hasenstein","year":"2012","unstructured":"Hasenstein JR, Kasmerchak K, Buehler D, Hafez GR, Cleary K, Moody JS, et al. Efficacy of Tie2 receptor antagonism in angiosarcoma. Neoplasia. 2012;14:131\u201340.","journal-title":"Neoplasia"},{"key":"4828_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jso.20766","volume":"97","author":"E Itakura","year":"2008","unstructured":"Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97:74\u201381.","journal-title":"J Surg Oncol"},{"key":"4828_CR7","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0002-9440(10)65729-X","volume":"153","author":"C Zietz","year":"1998","unstructured":"Zietz C, Rossle M, Haas C, Sendelhofert A, Hirschmann A, St\u00fcrzl M, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998;153:1425\u201333.","journal-title":"Am J Pathol"},{"key":"4828_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/modpathol.3880033","volume":"13","author":"AL Folpe","year":"2000","unstructured":"Folpe AL, Veikkola T, Valtola R, Weiss SW. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol. 2000;13:180\u20135.","journal-title":"Mod Pathol"},{"key":"4828_CR9","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1158\/0008-5472.CAN-09-2068","volume":"69","author":"CR Antonescu","year":"2009","unstructured":"Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175\u20139.","journal-title":"Cancer Res"},{"key":"4828_CR10","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/S0002-9440(10)65015-8","volume":"156","author":"JL Arbiser","year":"2000","unstructured":"Arbiser JL, Larsson H, Claesson-Welsh L, Bai X, LaMontagne K, Weiss SW, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. American J Pathol. 2000;156:1469\u201376.","journal-title":"American J Pathol."},{"key":"4828_CR11","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/S0002-9440(10)65088-2","volume":"156","author":"LF Brown","year":"2000","unstructured":"Brown LF, Dezube BJ, Tognazzi K, Dvorak HF, Yancopoulos GD. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. American J Pathol. 2000;156:2179\u201383.","journal-title":"American J Pathol"},{"key":"4828_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.lungcan.2008.10.031","volume":"65","author":"E Stacher","year":"2009","unstructured":"Stacher E, Gruber-Mosenbacher U, Halbwedl I, Dei Tos AP, Cavazza A, Papotti M, et al. The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: new potential therapeutic targets? Lung Cancer. 2009;65:49\u201355.","journal-title":"Lung Cancer"},{"key":"4828_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/ng.2921","volume":"46","author":"S Behjati","year":"2014","unstructured":"Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. 2014;46:376\u20139.","journal-title":"Nat Genet"},{"key":"4828_CR14","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","volume":"33","author":"I Ray-Coquard","year":"2015","unstructured":"Ray-Coquard I, Domont J, Tresch-Bruneel E, Bompas E, Cassier PA, Mir O, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial. J Clin Oncol. 2015;33:2797\u2013802.","journal-title":"J Clin Oncol"},{"key":"4828_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11523-013-0299-0","volume":"9","author":"N Penel","year":"2014","unstructured":"Penel N, Ray-Coquard I, Bal-Mahieu V, Chevreau C, Le Cesne A, Italiano A, et al. Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from phase II trial. Target Oncol. 2014;9:273\u20137.","journal-title":"Target Oncol"},{"key":"4828_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mds237","volume":"24","author":"M Agulnik","year":"2013","unstructured":"Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24:257\u201363.","journal-title":"Ann Oncol"},{"key":"4828_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00280-015-2689-8","volume":"75","author":"SP D\u2019Angelo","year":"2015","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA, Adkins DR, Perdekamp MT, Condy MM, et al. Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma. Cancer Chemother Pharmacol. 2015;75:629\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15_suppl","key":"4828_CR18","doi-asserted-by":"publisher","first-page":"11016","DOI":"10.1200\/JCO.2016.34.15_suppl.11016","volume":"34","author":"Steven Attia","year":"2016","unstructured":"Attia S, Sankhala KK, Riedel RF, Robinson SI, Conry RM, Boland PM, et al. A phase 1B\/ phase 2A study of TRC105 (Endoglin antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissuesarcoma (STS). J Clin Oncol. 2016;34:11016.","journal-title":"Journal of Clinical Oncology"},{"key":"4828_CR19","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/cncr.26599","volume":"118","author":"A Italiano","year":"2012","unstructured":"Italiano A, Cioffi A, Penel N, Levra MG, Delcambre C, Kalbacher E, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118:3330\u20136.","journal-title":"Cancer"},{"key":"4828_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/bjc.2012.328","volume":"107","author":"S Sleijfer","year":"2012","unstructured":"Sleijfer S, Gorlia T, Lamers C, Burger H, Blay JY, Le Cesne A, et al. Cytokine and angiogenic factors associated with efficacy and toxicity in advanced soft tissue sarcomA: an EORTC STBSG study. Br J Cancer. 2012;107:659\u201345.","journal-title":"Br J Cancer"},{"key":"4828_CR21","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3390\/cancers6031753","volume":"6","author":"A Martinetti","year":"2014","unstructured":"Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, et al. Circulating biomarkers in advanced colorectal patients randomly assigned to three bevacizumab-based regimens. Cancer. 2014;6:1753\u201368.","journal-title":"Cancer"},{"key":"4828_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1634\/theoncologist.2011-0465","volume":"17","author":"V Boige","year":"2012","unstructured":"Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17:1063\u201372.","journal-title":"Oncologist"},{"key":"4828_CR23","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.4143\/crt.2015.374","volume":"48","author":"YE Kim","year":"2016","unstructured":"Kim YE, Joo B, Park MS, Shin SJ, Ahn JB, Kim MJ. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate biomarker for bevacizumab in colorectal cancer liver metastasis: a single-arm exploratory trial. Cancer Res Treat. 2016;48:1210\u201321.","journal-title":"Cancer Res Treat"},{"key":"4828_CR24","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.1424024112","volume":"112","author":"RS Heist","year":"2015","unstructured":"Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, et al. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A. 2015;112:1547\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4828_CR25","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/bjc.2011.85","volume":"104","author":"F Loupakis","year":"2011","unstructured":"Loupakis F, Cremolini V, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevaciazumab schedule in metastatic colorectal cancer. Br J Cancer. 2011;104:1262\u20139.","journal-title":"Br J Cancer"},{"key":"4828_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","volume":"28","author":"S Kopetz","year":"2010","unstructured":"Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453\u20139.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4828-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T19:11:17Z","timestamp":1570734677000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4828-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4828"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4828-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]},"assertion":[{"value":"26 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study investigations were conducted after approval by the local Ethics Committee (Nord-Ouest IV Commit de Protection des Patients) on 9th March, 2010, and after the approval of the French Health Authority (AFSSAPS) on 12th April, 2010. Signed informed consent was obtained from each patient. The study was registered in the European Clinical Trials Register (EudraCT N\u00b0 2009\u2013017020-59) and in the US Clinical Trials Register (NCT01303497) and was conducted in agreement with the Declaration of Helsinki and International Conference on Harmonization of Good Clinical Practice guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"963"}}